KR101889392B1 - 안검하수증의 비-외과적 치료를 위한 조성물 및 방법 - Google Patents

안검하수증의 비-외과적 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101889392B1
KR101889392B1 KR1020137026050A KR20137026050A KR101889392B1 KR 101889392 B1 KR101889392 B1 KR 101889392B1 KR 1020137026050 A KR1020137026050 A KR 1020137026050A KR 20137026050 A KR20137026050 A KR 20137026050A KR 101889392 B1 KR101889392 B1 KR 101889392B1
Authority
KR
South Korea
Prior art keywords
oxymetazoline
eye
subject
ptosis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137026050A
Other languages
English (en)
Korean (ko)
Other versions
KR20140013013A (ko
Inventor
마크 엠.디. 실버버그
Original Assignee
붐, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 붐, 엘엘씨 filed Critical 붐, 엘엘씨
Publication of KR20140013013A publication Critical patent/KR20140013013A/ko
Application granted granted Critical
Publication of KR101889392B1 publication Critical patent/KR101889392B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020137026050A 2011-03-03 2012-02-24 안검하수증의 비-외과적 치료를 위한 조성물 및 방법 Active KR101889392B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161448949P 2011-03-03 2011-03-03
US61/448,949 2011-03-03
US13/218,584 2011-08-26
US13/218,584 US20120225918A1 (en) 2011-03-03 2011-08-26 Compositions and Methods for Non-Surgical Treatment of Ptosis
US13/270,577 2011-10-11
US13/270,577 US8357714B2 (en) 2011-03-03 2011-10-11 Compositions and methods for non-surgical treatment of ptosis
PCT/US2012/026496 WO2012118704A1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis

Publications (2)

Publication Number Publication Date
KR20140013013A KR20140013013A (ko) 2014-02-04
KR101889392B1 true KR101889392B1 (ko) 2018-08-17

Family

ID=46753678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137026050A Active KR101889392B1 (ko) 2011-03-03 2012-02-24 안검하수증의 비-외과적 치료를 위한 조성물 및 방법

Country Status (24)

Country Link
US (8) US20120225918A1 (enExample)
EP (2) EP3653205A3 (enExample)
JP (1) JP6106100B2 (enExample)
KR (1) KR101889392B1 (enExample)
CN (1) CN103501771B (enExample)
AU (1) AU2012223615B2 (enExample)
BR (1) BR112013022094A2 (enExample)
CA (1) CA2827285C (enExample)
CY (1) CY1122565T1 (enExample)
DK (1) DK2680829T3 (enExample)
ES (1) ES2750123T3 (enExample)
HR (1) HRP20192266T1 (enExample)
HU (1) HUE046740T2 (enExample)
LT (1) LT2680829T (enExample)
MX (1) MX345042B (enExample)
PL (1) PL2680829T3 (enExample)
PT (1) PT2680829T (enExample)
RS (1) RS59636B1 (enExample)
RU (1) RU2582392C2 (enExample)
SG (1) SG192801A1 (enExample)
SI (1) SI2680829T1 (enExample)
SM (1) SMT201900718T1 (enExample)
WO (1) WO2012118704A1 (enExample)
ZA (1) ZA201307262B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
BR112014006607A2 (pt) 2011-09-20 2017-04-25 Allergan Inc composições e métodos para tratamento de presbiopia, hiperopia leve e astigmatismo irregular
AU2014262960A1 (en) * 2013-05-06 2015-11-26 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
CA2869060A1 (en) * 2014-07-28 2016-01-28 Queen's University At Kingston Dosage forms and methods for diagnosing sympathetic nervous system dysfunction
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN106726115B (zh) * 2016-12-22 2023-01-20 上海交通大学医学院附属第九人民医院 一种眼睑功能矫正器
CN106938039A (zh) * 2017-03-29 2017-07-11 卢仁华 眼睑下垂的治疗药物
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN108635434A (zh) * 2018-06-24 2018-10-12 吴安相 一种治疗眼睑下垂的侗族中药配方
SG11202104410SA (en) * 2018-11-26 2021-06-29 Cellix Bio Private Ltd Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
AU2021259787A1 (en) * 2020-04-23 2022-12-22 Okogen, Inc. Treatment of viral conjunctivitis
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503061A (ja) 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1117588B (de) 1960-09-30 1961-11-23 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates
US3670087A (en) * 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3227741A1 (de) 1982-07-24 1984-01-26 Hoechst Ag, 6230 Frankfurt 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung
FR2549015B1 (fr) * 1983-07-13 1986-06-13 Oreal Ensemble compte-gouttes
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
WO1998047510A1 (en) * 1997-04-24 1998-10-29 Taisho Pharmaceutical Co., Ltd. Eye drops
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
JP2004509920A (ja) * 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
US7780976B2 (en) * 2002-05-30 2010-08-24 Eye Care And Cure, Asia Apparatus and method for delivering controlled quantities of one or more agents to the eye
EP1517673A1 (en) * 2002-06-20 2005-03-30 Novartis Consumer Health S.A. Nasal composition comprising a mucopolysaccharide and propylene glycol
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7022740B2 (en) 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP4942328B2 (ja) * 2004-11-01 2012-05-30 ロート製薬株式会社 ビタミンｂ６類含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4956981B2 (ja) * 2005-01-05 2012-06-20 大正製薬株式会社 オキシメタゾリン含有水性組成物
TWI454286B (zh) 2006-03-17 2014-10-01 Johnson & Johnson Vision Care 安定氧化性不安定組合物之方法
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
US8466203B2 (en) 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
EP3943069B1 (en) * 2009-03-17 2024-11-27 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
CA2764477A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20130190317A1 (en) 2010-08-06 2013-07-25 Galderma Research & Development Snc Combination of compounds for treating or preventing skin diseases
CA2819633C (en) 2010-12-03 2019-04-23 Allergan, Inc. Pharmaceutical cream compositions and methods of use
AU2012217858A1 (en) * 2011-02-15 2013-09-05 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015191917A1 (en) 2014-06-11 2015-12-17 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503061A (ja) 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物

Also Published As

Publication number Publication date
JP2014506927A (ja) 2014-03-20
AU2012223615B2 (en) 2017-03-02
SG192801A1 (en) 2013-09-30
JP6106100B2 (ja) 2017-03-29
BR112013022094A2 (pt) 2017-06-27
SI2680829T1 (sl) 2020-02-28
CA2827285A1 (en) 2012-09-07
RS59636B1 (sr) 2020-01-31
EP2680829A1 (en) 2014-01-08
US9867808B2 (en) 2018-01-16
CN103501771A (zh) 2014-01-08
ES2750123T3 (es) 2020-03-25
WO2012118704A1 (en) 2012-09-07
US20200360345A1 (en) 2020-11-19
CN103501771B (zh) 2016-05-11
SMT201900718T1 (it) 2020-01-14
AU2012223615A1 (en) 2013-10-24
HRP20192266T1 (hr) 2020-03-20
US20220218669A1 (en) 2022-07-14
ZA201307262B (en) 2015-02-25
EP3653205A3 (en) 2020-08-26
US20200009114A1 (en) 2020-01-09
CA2827285C (en) 2019-05-07
US20180338953A1 (en) 2018-11-29
DK2680829T3 (da) 2019-11-18
MX345042B (es) 2017-01-16
US20160038465A1 (en) 2016-02-11
EP2680829B1 (en) 2019-09-25
LT2680829T (lt) 2019-12-27
US20120225918A1 (en) 2012-09-06
RU2582392C2 (ru) 2016-04-27
US8357714B2 (en) 2013-01-22
PT2680829T (pt) 2019-12-10
US9018240B2 (en) 2015-04-28
US20120225919A1 (en) 2012-09-06
RU2013142602A (ru) 2015-04-10
US10912765B2 (en) 2021-02-09
US20120225920A1 (en) 2012-09-06
KR20140013013A (ko) 2014-02-04
CY1122565T1 (el) 2021-01-27
HUE046740T2 (hu) 2020-03-30
PL2680829T3 (pl) 2020-03-31
EP3653205A2 (en) 2020-05-20
MX2013009597A (es) 2014-01-08
NZ614719A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
KR101889392B1 (ko) 안검하수증의 비-외과적 치료를 위한 조성물 및 방법
JP2011503061A (ja) 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物
US20210177807A1 (en) Compositions for the treatment and prevention of eyelid swelling
JP2009535342A (ja) 眼瞼腫脹の予防および処置のための組成物
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
US20240122974A1 (en) Treatment of myopia
HK40028636A (en) Oxymetazoline for Topical Ophthalmic Administration and Uses Thereof
HK1191223A (en) Compositions and methods for non-surgical treatment of ptosis
HK1191223B (en) Compositions and methods for non-surgical treatment of ptosis
NZ614719B2 (en) Compositions and methods for non-surgical treatment of ptosis
US20240225978A1 (en) Methods and compositions for pharmacological treatment of blepharoptosis
CN101460152A (zh) 治疗以及预防眼皮肿胀的组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8